<DOC>
	<DOCNO>NCT02675556</DOCNO>
	<brief_summary>This study intend evaluate safety potential efficacy Allogeneic Human Mesenchymal Stem Cell Infusion versus placebo patient Treatment Resistant Depression .</brief_summary>
	<brief_title>Allogeneic Human Mesenchymal Stem Cells ( hMSCs ) Infusion Patients With Treatment Resistant Depression</brief_title>
	<detailed_description>This phase I study , eighty ( 80 ) patient fulfil inclusion/exclusion criterion 's randomly assign receive allogeneic Human Mesenchymal Stem Cell ( hMSCs ) placebo 1:1 blinded fashion . 40 patient receive single administration allogeneic hMSCs another 40 patient receive single administration Placebo 1:1 blind fashion . Following infusion , patient follow 2 , 4 , 6 , 8 , 10 12 week 's post-infusion complete safety efficacy assessment . Patients additionally follow 12 month post-infusion .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Provide write informed consent . Subjects age equal great 18 equal less 75 year time signing Informed Consent Form . Diagnosis Treatment resistant depression ( Failed least two adequate trial antidepressant monotherapy antidepressant augmentation antipsychotic lithium current episode ) Patients receive third treatment enter responded current treatment . Experiencing current Major Depressive Episode ( fulfil Structured clinical interview Diagnostic Statistical Manual Mental Disorders ( DSM V ) criterion per Structured Clinical Interview DSM ( SCID ) categorical diagnosis , Hamilton Depression Rating Scale Depression ( HAMD ) ) Hamilton Depression Rating Scale 21item score great 18 Adequacy previous fail antidepressant trial define use standard criterion Massachusetts General Hospital ( MGH ) patient score great 2.5 Increased inflammation ( [ Serum CRP ] great 3.0 mg/L ) In order participate study , patient Must Not : Be female pregnant , nursing , childbearing potential , practice effective contraceptive method . ( Female patient must undergo blood urine pregnancy test screening within 36 hour prior infusion . ) Female subject must Follicle stimulate hormone ( FSH ) less 25.8 IU/L Inability perform assessment require . Clinically important abnormal screen laboratory value , include limited : hemoglobin &lt; 8 g/dl , white blood cell count &lt; 3000/mm3 , platelet &lt; 80,000/mm3 , International Normalized Ratio ( INR ) &gt; 1.5 due reversible cause ( i.e . Coumadin ) , aspartate transaminase , alanine transaminase , alkaline phosphatase &gt; 3 time upper limit normal , total bilirubin &gt; 1.8 mg/dl ( unless due benign cause ) . Active medical condition could cause exacerbate depressive symptom ( e.g. , hypothyroidism , anemia ) Serious comorbid illness condition ( Such bipolar , schizophrenia schizoaffective disorder ) , opinion investigator , may compromise safety compliance patient preclude successful completion study . Have acute suicidality Prior history suicide attempt Active psychotic disorder , eat disorder , substance use disorder within 6 month enrollment Treatment psychotropic ( include hypnotic ) , steroidal , anti inflammatory medication ( include Non steroid AntiInflammatory Drug ) within 2 week treatment randomization 6 week fluoxetine . First major depressive episode 50 year age . Have know allergy penicillin streptomycin . Hypersensitivity dimethyl sulfoxide ( DMSO ) . Have clinical history malignancy within 5 year ( i.e. , patient prior malignancy must disease free 5 year ) , except curatively treat basal cell carcinoma , squamous cell carcinoma , melanoma situ cervical carcinoma . Have nonpulmonary condition limit lifespan less 1 year . Have history drug alcohol abuse within past 24 month . Be serum positive HIV , Hepatitis B surface antigen Viremic hepatitis C. Be currently participate ( participate within previous 30 day ) investigational therapeutic device trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Depression</keyword>
</DOC>